Retifanlimab Drug Asset Due Diligence Report 2026

This Retifanlimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Retifanlimab can convert its Monoclonal antibody profile and PD-1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Retifanlimab (query alias: retifanlimab)
Modality / target	Monoclonal antibody; PD-1; PD-1 inhibitors
Highest global status	Approved
Originator	MacroGenics, Inc.
Active developers	MacroGenics, Inc., Incyte Corp., Incyte Biosciences International SARL

The MCP disease footprint includes Merkel Cell Carcinoma, Anal canal squamous cell carcinoma, Metastatic Merkel Cell Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07425054	Phase 2	Recruiting	33	1-year Disease-free survival (DFS) by response subgroup
NCT07677579	Phase 2	Not yet recruiting	26	Intent for Curative Surgery Post-Treatment
NCT07468136	Phase 1/2	Recruiting	33	Best tolerable dose level of Difluoromethylornithine (DFMO, or eflornithine) (phase I)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer.

Phase 3; n=147; evaluation: Positive. Reported fields: Cognitive = 1.5 point

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma

Phase 2; n=30; evaluation: Positive. Reported fields: ORR = 20.0 % ( 8 - 39)

A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2; n=176; evaluation: not stated. Reported fields: Progeression-free Survival (PFS)(Median) = 5.3 months (95% Confidence Interval, 2.1 - 7.9); Progeression-free Survival (PFS)(Median): Hazard Ratio (HR) = 1.05(95% CI, 0.66 - 1.67), P-Value = 0.5856; Hazard Ratio (HR) = 1.09(95% CI, 0.69 - 1.72), P-Value = 0.6434; Progeression-free Survival (PFS)(Median) = 5.8 months (95% Confidence Interval, 3.7 - 7.6)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Retifanlimab addresses Merkel Cell Carcinoma, Anal canal squamous cell carcinoma, Metastatic Merkel Cell Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 7 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-05-04	MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement	Approved	US$60.0M upfront; US$20.0M milestones
2025-12-22	Handok had expanded its portfolio by signing an agreement for Zynyz with Incyte, an anal cancer treatment currently awaiting approval in Korea	Approved	Financial terms not disclosed
2025-06-12	Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination therapies using CDK4 inhibitors with PD-1 axis binding antagonists”. The milestone feed surfaced a patent-application signal described as “Resiquimod in combination with a PD-1 or PD-l1 antagonist for treating cancer”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO